loading...| Preferred Name |
tranexamic acid |
|
| Synonyms |
Cyklokapron |
|
| Definitions |
A synthetic derivative of the amino acid lysine with antifibrinolytic activity. With strong affinity for the five lysine-binding sites of plasminogen, transexamic acid competitively inhibits the activation of plasminogen to plasmin, resulting in inhibition of fibrinolysis; at higher concentrations, this agent noncompetitively inhibits plasmin. This agent has a longer half-life, is approximately ten times more potent, and is less toxic than aminocaproic acid, which possesses similar mechanisms of action. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47765" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47765" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000453549 |
|
| altLabel |
Cyklokapron |
|
| cui |
C0040613 C0591311 |
|
| DATE FIRST PUBLISHED |
2005-10-24 |
|
| Date last modified |
2006-09-28 |
|
| definition |
A synthetic derivative of the amino acid lysine with antifibrinolytic activity. With strong affinity for the five lysine-binding sites of plasminogen, transexamic acid competitively inhibits the activation of plasminogen to plasmin, resulting in inhibition of fibrinolysis; at higher concentrations, this agent noncompetitively inhibits plasmin. This agent has a longer half-life, is approximately ten times more potent, and is less toxic than aminocaproic acid, which possesses similar mechanisms of action. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47765" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47765" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C47765 |
|
| notation |
CDR0000453549 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
tranexamic acid |
|
| tui |
T109 T121 |